It’s time for a booster: here’s your 19th dose of Future Virology!

Figures & data

Table 1. Top articles in Volume 18 of Future Virology by downloads^†.

Title	Study	Article type	Volume (issue)	Ref.
A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?	Shafiee, Teymouri Athar and Mozhgani	Editorial	18(3)	[1]
Diagnosing COVID-19: diagnostic importance of detecting E gene of the SARS-CoV-2 genome	Barjaktarović et al.	Short Communication	18(1)	[2]
COVID-19 post vaccination neuronal adverse events: probable mechanisms and treatment possibilities	Mannan Baig et al.	Editorial	18(7)	[3]

† As of September 2023.

Table 2. Top articles in Volume 18 of Future Virology by citations^†.

Title	Study	Article type	Volume (issue)	Ref.
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes	Nag et al.	Review	18(5)	[4]
Natural killer cells in COVID-19: from infection, to vaccination and therapy	Zafarani et al.	Review	18(3)	[5]
Evidence-based policies in public health to address COVID-19 vaccine hesitancy	Chirico and Teixeira da Silva	Perspective	18(4)	[6]

† As of September 2023.

Table 3. Top Plain Language Summaries in Volume 18 of Future Virology by downloads^†.

Title	Study	Article type	Volume (issue)	Ref.
Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old	Frenck et al. for the C4591001 Clinical Trial Group	Plain Language Summary	18(1)	[9]
Plain language summary of a clinical trial evaluating mRNA-1273, Moderna’s mRNA-based COVID-19 vaccine, in children 6 through 11 years of age	Creech et al. for the KidCOVE Study Group	Plain Language Summary	18(10)	[10]

† As of September 2023.

Figure 1. Readership demographic of Future Virology in 2023.

Figure 2. Authorship demographic of Future Virology in 2023.

Shafiee A , TeymouriAthar MM , MozhganiSH. A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?Fut. Virol.18(3), 137–139 (2023).

 Web of Science ®Google Scholar

Barjaktarović I , StojčevićMaletić J , VučinićN , MilutinovićA , GrujičićM , ČabarkapaV. Diagnosing COVID-19: diagnostic importance of detecting E gene of the SARS-CoV-2 genome. Fut. Virol.18(1), 31–38 (2023).

 Web of Science ®Google Scholar

Baig AM , GerlachJ , SalunkeP , JesseyR , RoseR. COVID-19 post vaccination neuronal adverse events: probable mechanisms and treatment possibilities. Fut. Virol.18(7), 399–401 (2023).

 Web of Science ®Google Scholar

Nag S , MandalS , MukherjeeO , MukherjeeS , KunduR. DPP-4 inhibitors as a savior for COVID-19 patients with diabetes. Fut. Virol.18(5), 321–333 (2023).

 Web of Science ®Google Scholar

Zafarani A , RazizadehMR , PashangzadehS , AmirzargarMR , Taghavi-FarahabadiM , MahmoudiM. Natural killer cells in COVID-19: from infection, to vaccination and therapy. Fut. Virol.18(3), 177–191 (2023).

 Web of Science ®Google Scholar

Chirico F , Teixeirade Silva JA. Evidence-based policies in public health to address COVID-19 vaccine hesitancy. Fut. Virol.18(4), 261–273 (2023).

 Web of Science ®Google Scholar

Frenck RW , KleinNP , KitchinNet al. ;for the C4591001 Clinical Trial Group. Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years old. Fut. Virol.18(1), 9–20 (2023).

 Web of Science ®Google Scholar

Creech CB , AndersonE , BerthaudVet al. ; for the KidCOVE Study Group. Plain language summary of a clinical trial evaluating mRNA-1273, Moderna’s mRNA-Based COVID-19 vaccine, in children 6 through 11 years of age. Fut. Virol.18(10), 615–620 (2023).

 Google Scholar